Inactive Instrument

Highlights Organovo Holdings Inc Nyse

Equities

US68620A1043

End-of-day quote Nyse Other stock markets
- ^USD	-

15/04	Organovo's fatty liver disease drug meets main goal in mid-stage study	RE
15/04	Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Organovo's fatty liver disease drug meets main goal in mid-stage study	15/04	RE
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15/04	CI
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	25/01	CI
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	06/12	CI
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	10/11	CI
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	08/11	CI
Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23/23/23	CI
Organovo Holdings, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	14/23/14	CI
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates	15/22/15	CI
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/22/11	CI
Organovo Holdings, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	12/22/12	CI
Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	11/22/11	CI
Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease	17/22/17	CI
Organovo, BICO Reach Patent License Agreement for 3D Bioprinting	23/22/23	MT
Organovo Holdings, Inc. and BICO Reach Licensing Agreement on Bioprinting Patents	23/22/23	CI
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	15/22/15	CI
Organovo Holdings' Patents Survive Petition With Patent Trial and Appeal Board	03/22/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Organovo Holdings Inc Nyse

Equities

US68620A1043

Highlights

Filters